Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) FCF Margin (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed FCF Margin for 1 consecutive years, with 26850.85% as the latest value for Q2 2025.

  • On a quarterly basis, FCF Margin changed N/A to 26850.85% in Q2 2025 year-over-year; TTM through Dec 2025 was 15.41%, a N/A change, with the full-year FY2025 number at 0.64%, changed N/A from a year prior.
  • FCF Margin was 26850.85% for Q2 2025 at Neuphoria Therapeutics, up from 76.36% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 26850.85% in Q2 2025 to a low of 76.36% in Q1 2025.